| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00006676-199704000-00003 |
| P698 | PubMed publication ID | 9094152 |
| P2093 | author name string | W Du | |
| K Singh | |||
| V K Vaitkevicius | |||
| F H Sarkar | |||
| J D Crissman | |||
| M C Dugan | |||
| L Biernat | |||
| R Kucway | |||
| S T Dergham | |||
| P433 | issue | 3 | |
| P921 | main subject | pancreatic adenocarcinoma | Q18556189 |
| P304 | page(s) | 229-236 | |
| P577 | publication date | 1997-04-01 | |
| P1433 | published in | Pancreas | Q15762014 |
| P1476 | title | HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival | |
| P478 | volume | 14 |
| Q40552877 | Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines |
| Q54679578 | Clinical significance of K-ras and c-erbB-2 mutations in pancreatic adenocarcinoma and chronic pancreatitis. |
| Q36430542 | Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts |
| Q35828693 | Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial |
| Q36142444 | Ductal adenocarcinoma of the pancreas: Expression of growth factor receptors, oncogenes and suppressor genes, and their relationship to pathological features, staging and survival. |
| Q89989625 | Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target |
| Q36622264 | Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma |
| Q46385316 | Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases |
| Q34887225 | HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study. |
| Q24814451 | HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC). |
| Q43455376 | HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma |
| Q77068387 | Identification of HER-2/neu overexpression and the clinical course of lung carcinoma in non-smokers with chronic lymphocytic leukemia |
| Q44338521 | Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma |
| Q34684162 | Immunotherapy for pancreatic cancer: current concepts |
| Q34311382 | Innovative treatments for pancreatic cancer. |
| Q34446262 | Molecular pathogenesis of pancreatic ductal adenocarcinoma and clinical implications. |
| Q34236658 | Monoclonal antibody therapy |
| Q44860005 | Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma |
| Q83021187 | Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer |
| Q74092381 | Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma |
| Q43723222 | Ribozyme targeting of HER-2 inhibits pancreatic cancer cell growth in vivo |
| Q34494019 | The molecular targets for the diagnosis and treatment of pancreatic cancer |
| Q36773130 | The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer |
| Q40809042 | Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). |
Search more.